Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$798.99 USD

798.99
1,216,922

-7.15 (-0.89%)

Updated Nov 5, 2024 11:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Appeals Court Rules Against J&J but Cuts Talc- Powder Verdict

by Zacks Equity Research

J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.

Manaswita Ghosh Dutta headshot

3 Stocks to Buy on New Drug Approvals by FDA

by Manaswita Ghosh Dutta

In May, the Food and Drug Administration approved as many as 13 new drugs, higher than the eight approved in the same month last year.

Patterson Companies (PDCO) Q4 Earnings Top Estimates, Up Y/Y

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal fourth-quarter results reflect dismal performance by Dental and Animal Health segments.

AbbVie's (ABBV) sBLA for Botox Gets Acceptance From FDA

by Zacks Equity Research

AbbVie's (ABBV) sBLA for expanding the label of Botox for use in pediatric patients with neurogenic detrusor overactivity gets acceptance from the FDA.

Merck's Pneumococcal Vaccine Meets Goal in Two Adult Studies

by Zacks Equity Research

Merck's (MRK) development program on V114 comprises 16 studies, evaluating safety, tolerability and immunogenicity of V114 in a variety of patient populations.

Pfizer Begins Four Phase III Studies on Vaccine Candidates

by Zacks Equity Research

Pfizer (PFE) begins four phase III studies on vaccine candidates. EMA validates its label expansion application for Bavencio in first-line bladder cancer.

What's in Store for Patterson Companies' (PDCO) Q4 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect solid performance at Dental segment.

Innoviva (INVA) Looks Good: Stock Adds 8.9% in Session

by Zacks Equity Research

Innoviva (INVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

The Zacks Analyst Blog Highlights: Eli Lilly & Company, AstraZeneca, AbbVie and Bristol-Myers Squibb

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly & Company, AstraZeneca, AbbVie and Bristol-Myers Squibb

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approvals to MRK, LLY, NVS and GSK's Drugs

by Kinjel Shah

FDA approves expanded labels of Merck (MRK), Novartis (NVS) and Glaxo (GSK) drugs and Lilly's (LLY) new insulin.

Kinjel Shah headshot

Buy These 4 Big Drugmakers to Keep Coronavirus Woes at Bay

by Kinjel Shah

Here we highlight four large drugmakers that can prove to be safe bets amid the coronavirus crisis.

PTC Therapeutics to Commence Phase II/III Coronavirus Study in US

by Zacks Equity Research

PTC Therapeutics (PTCT) gets an FDA sanction to begin a phase II/III study on its DHODH inhibitor PTC299 as a potential treatment of COVID-19. The study will start in the United States shortly.

The Zacks Analyst Blog Highlights: Procter & Gamble, Eli Lilly, Thermo Fisher Scientific, Costco Wholesale and Shopify

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Procter & Gamble, Eli Lilly, Thermo Fisher Scientific, Costco Wholesale and Shopify

Company News for Jun 17, 2020

by Zacks Equity Research

Companies in the news are: WW, LLY, CLIR, CVU

Novartis' (NVS) Cosentyx Gets FDA Nod for New Indication

by Zacks Equity Research

Novartis' (NVS) Cosentyx wins FDA approval for a fourth indication ??? active non-radiographic axial spondyloarthritis (nr-axSpA).

Lilly Gains as Verzenio Meets Early Breast Cancer Study Goal

by Zacks Equity Research

Lilly's (LLY) phase III study on Verzenio in HR+, HER2- early breast cancer met its primary endpoint of invasive disease-free survival.

Lilly Begins Phase III Study on Olumiant for Coronavirus

by Zacks Equity Research

Lilly's (LLY) Olumiant is being studied for COVID-19 on the assumption that JAK1 and JAK2 inhibition may reduce cytokine storm, a complication associated with COVID-19.

Sheraz Mian headshot

Top Analyst Reports for Procter & Gamble, Eli Lilly & Thermo Fisher

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Eli Lilly (LLY) and Thermo Fisher Scientific (TMO).

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Eli Lilly (LLY) closed at $141.52, marking a -1.41% move from the previous day.

Glaxo (GSK) HIV Drug Tivicay Gets FDA Approval for Toddlers

by Zacks Equity Research

FDA approves Glaxo's (GSK) oral suspension formulation of its three-drug regimen for HIV, Tivicay, as a treatment for patients aged at least four weeks and weighing at least 3kg.

Merck's Gardasil Gets FDA Approval for Head and Neck Cancers

by Zacks Equity Research

FDA grants accelerated approval for label expansion application of Merck's (MRK) human papillomavirus vaccine, Gardasil, to include oropharyngeal and other head and neck cancers.

This is Why Eli Lilly (LLY) is a Great Dividend Stock

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Kinjel Shah headshot

Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals

by Kinjel Shah

J&J (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.

AbbVie Inks Deal With Genmab, Announces ADC Candidate Data

by Zacks Equity Research

AbbVie (ABBV) signs deal with Genmab to jointly develop three early-stage bispecific antibody product candidates. Its novel ADC candidate, ABBV-3373 demonstrates clinical activity in study.

Pfizer's Eczema Candidate Meets All Goals in Study on Teens

by Zacks Equity Research

Pfizer's (PFE) investigational eczema treatment, abrocitinib, succeeds in a late-stage study under the JADE program in patients aged 12 years and above.